

AMENDMENTS TO THE CLAIMS

Please replace all previous listings, and versions, of the claims with the following claims, where text to be added is indicated by underlining and text to be omitted is indicated by strikethrough:

1-38. (canceled)

39. (currently amended) A kit comprising:

a multimeric compound that binds to at least two P-Selectin Glycoprotein-1 (PSGL-1) proteins on the surface of a T cell, wherein the multimeric compound comprises two polypeptide chains, each of the polypeptide chains comprising (i) a binding domain that binds to PSGL-1, and (ii) a heterologous amino acid sequence, wherein the polypeptide chains are linked via the heterologous amino acid sequence to form the multimeric compound, wherein the binding of the multimeric compound to the at least two PSGL-1 proteins on the surface of the T cell induces a signal transduction pathway that results in ~~the~~ death of the T cell; and

instructions for use of the multimeric compound to treat inflammation, autoimmunity, transplant rejection, an allergic condition, or a T cell cancer,

wherein the multimeric compound is a homo-multimeric anti-PSGL-1 antibody.

40. (new) The kit according to claim 39, wherein the homo-multimeric anti-PSGL-1 antibody is a chimeric anti-PSGL-1 antibody.

41. (new) The kit according to claim 39, wherein the homo-multimeric anti-PSGL-1 antibody is a humanized anti-PSGL-1 antibody.